| 16/12/2011 |
Appendix 3B |
| 08/12/2011 |
Change of Director’s Interest Notice |
| 08/12/2011 |
Change of Director’s Interest Notice |
| 08/12/2011 |
Change of Director’s Interest Notice |
| 08/12/2011 |
Notice of Initial Substantial Holder |
| 02/12/2011 |
Dispatch of Rights Issue Holdings Statements |
| 01/12/2011 |
Completed Midkine Study for Normal Reference Range |
| 29/11/2011 |
Rights Issue and Placement of Shortfall |
| 25/11/2011 |
Amended Constitution |
| 25/11/2011 |
Results of Meeting |
| 14/11/2011 |
US Patent for the Prevention or Treatment of Ischemia |
| 09/11/2011 |
Non-Renounceable Rights Issue Despatch of Offer Document |
| 31/10/2011 |
Appendix 4C |
| 27/10/2011 |
Pro Forma Appendix 3B |
| 26/10/2011 |
Annual Report to Shareholders |
| 26/10/2011 |
Non-Renounceable Rights Issue |
| 26/10/2011 |
Notice of Annual General Meeting / Proxy Form |
| 20/10/2011 |
Amended Constitution of November 2008 |
| 12/10/2011 |
CE Marking of Cellmid’s Midkine ELISA |
| 06/10/2011 |
Completed Humanisation of First Ever Anti-midkine Antibody |
| 30/09/2011 |
EGM Presentation by the CEO |
| 30/09/2011 |
Results of meeting |
| 31/08/2011 |
Notice of Extraordinary General Meeting Proxy |
| 29/08/2011 |
Appendix 4E and Preliminary Final Report |
| 17/08/2011 |
Change of Director’s Interest Notice |
| 02/08/2011 |
Completed GMP Manufacture of Midkine Test |
| 25/07/2011 |
Appendix 4C |
| 10/06/2011 |
Appendix 3B |
| 31/05/2011 |
Change of Director’s Interest Notice |
| 25/05/2011 |
Celera license update |
| 19/04/2011 |
Appendix 4C – quarterly |
| 16/04/2011 |
Appendix 3B |
| 14/04/2011 |
Appendix 3B |
| 13/04/2011 |
Cellmid Signs Antibody Humanisation Collaboration |
| 11/04/2011 |
Completion of Proof of Concept Study for Heart Attack |
| 07/03/2011 |
Change of Director’s Interest Notice |
| 22/02/2011 |
Cellmid News |
| 18/02/2011 |
Change of Director’s Interest Notice |
| 02/02/2011 |
Appendix 3B |
| 31/01/2011 |
Appendix 4C – quarterly |
| 10/01/2011 |
Appendix 3B |
| 05/01/2011 |
Cellmid Share Trading Policy |
